Product Description
Mebendazole is used to treat infections caused by worms. It works by keeping the worm from absorbing sugar (glucose), so that the worm loses energy and dies. (Sourced from: https://www.mayoclinic.org/drugs-supplements/mebendazole-oral-route/side-effects/drg-20064631?p=1)
Mechanisms of Action: Tubulin Inhibitor,Glucose Uptake Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Philippines, Tanzania, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Ancylostomiasis|Communicable Diseases|Hookworm Infections|Trichuriasis
Phase 2: Astrocytoma|Glioblastoma|Gliosarcoma|Optic Nerve Glioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CCMC1411 | P2 |
Completed |
Gliosarcoma|Optic Nerve Glioma|Glioblastoma|Astrocytoma |
2024-04-01 |
30% |
2024-11-27 |
Primary Endpoints|Treatments |
| TREMO-Siargao | P3 |
Not yet recruiting |
Trichuriasis|Hookworm Infections|Ancylostomiasis|Communicable Diseases |
2025-12-01 |
8% |
2025-01-30 |
Primary Endpoints|Treatments |
| TREMO-Pemba | P3 |
Not yet recruiting |
Hookworm Infections|Ancylostomiasis|Communicable Diseases|Trichuriasis |
2025-09-01 |
8% |
2024-12-19 |
Primary Endpoints |
| 2016-000728-24 | P3 |
Active, not recruiting |
Unknown |
2018-06-11 |
2025-07-05 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/09/2024 |
News Article |
Public advisory - Unauthorized health products seized from Vanette Keast Health Consulting in Red Deer, Alberta may pose serious health risks |
|
01/17/2024 |
News Article |
Trading Heats Up For This Micro Cap |
|
10/03/2023 |
News Article |
[2023-2031] 5G Wireless Base Station Market Latest Sales Figure Signals more Opportunities Ahead |
|
10/03/2023 |
News Article |
Cat Hairball Remedies Market Size, Growth & Forecast Report [2030] |